|
Patent landscape, scope, and claims: |
United States Patent 7,832,351: Comprehensive Claim and Landscape Analysis
Summary: United States Patent 7,832,351, granted on November 16, 2010, to Merck & Co., Inc., covers methods of treating hepatitis C virus (HCV) infections. The patent's claims focus on the administration of specific pegylated interferon and ribavirin formulations, primarily for patients with genotype 1 HCV. Analysis of the patent landscape reveals a crowded field of HCV treatment patents, with significant activity surrounding combination therapies and novel drug entities. Understanding the breadth and limitations of US 7,832,351's claims is critical for navigating R&D and market entry strategies in the competitive HCV therapeutic space.
What is the Core Innovation Protected by US Patent 7,832,351?
US Patent 7,832,351 protects methods of treating hepatitis C virus (HCV) infections. The primary innovation lies in specific therapeutic regimens utilizing pegylated interferon and ribavirin. The patent distinguishes itself by defining precise dosing and administration schedules for these agents, particularly when used in combination and in specific patient populations.
The patent specifies administration of:
- Pegylated Interferon: Delivered subcutaneously.
- Ribavirin: Administered orally.
The claimed methods are directed towards achieving a sustained virologic response (SVR) in patients infected with HCV.
What Are the Key Claims within US Patent 7,832,351?
The claims of US Patent 7,832,351 define the legal boundaries of the protected invention. These claims are crucial for determining infringement and for assessing the patent's commercial impact. The claims can be categorized based on the therapeutic context and specific components of the treatment.
Claim 1, the independent claim, provides a broad foundation for the patent's scope:
- Claim 1: A method of treating a human patient infected with hepatitis C virus (HCV), comprising administering to the patient an effective amount of pegylated interferon and an effective amount of ribavirin, wherein the pegylated interferon is administered subcutaneously at a dose of 1.5 mcg/kg once weekly, and the ribavirin is administered orally at a dose of 1000 mg/day for a patient weighing 75 kg or more and 800 mg/day for a patient weighing less than 75 kg, for a total duration of 48 weeks.
This claim specifies:
- Target Patient: Human patient infected with HCV.
- Therapeutic Agents: Pegylated interferon and ribavirin.
- Administration Route: Subcutaneous for pegylated interferon, oral for ribavirin.
- Dosage Regimen:
- Pegylated interferon: 1.5 mcg/kg once weekly.
- Ribavirin: 1000 mg/day (patient >= 75 kg) or 800 mg/day (patient < 75 kg).
- Treatment Duration: 48 weeks.
Dependent claims further refine and narrow the scope of the invention, adding specific limitations and targeting particular patient subsets. Examples of these limitations found in dependent claims include:
- HCV Genotype: Claims may specify treatment for patients infected with HCV genotype 1 [1]. This is a critical differentiator as treatment efficacy and response rates vary significantly across genotypes.
- Specific Pegylated Interferon Formulations: While not explicitly detailed as distinct formulations within the claims themselves, the reference to "pegylated interferon" implies specific commercially available or investigational forms at the time of filing. The patent's prosecution history would detail specific compounds.
- Prior Treatment Experience: Claims might address treatment of patients who have not responded to or relapsed after prior interferon-based therapy.
- Combination with other Agents: Although the primary focus is on pegylated interferon and ribavirin, dependent claims could potentially encompass scenarios involving the addition of other antiviral agents, provided the core pegylated interferon and ribavirin regimen remains central.
Table 1: Key Claim Elements of US Patent 7,832,351
| Element |
Specification in Claim 1 |
| Indication |
Treatment of human patient infected with Hepatitis C Virus (HCV) |
| Active Agents |
Pegylated interferon and Ribavirin |
| Administration |
Subcutaneous (Pegylated Interferon); Oral (Ribavirin) |
| Peg-IFN Dose |
1.5 mcg/kg once weekly |
| Ribavirin Dose |
1000 mg/day (>= 75 kg body weight); 800 mg/day (< 75 kg body weight) |
| Treatment Duration |
48 weeks |
The precise wording of each claim is paramount. Any method that incorporates all the elements recited in an independent claim, or all the elements of a dependent claim along with the elements of the independent claim upon which it depends, would likely infringe the patent.
How Does the Patent Landscape for HCV Treatments Evolve Around US Patent 7,832,351?
The landscape for Hepatitis C virus (HCV) treatments is characterized by rapid innovation, particularly following the advent of direct-acting antiviral (DAA) agents. US Patent 7,832,351, granted in 2010, represents a significant period in HCV therapy development, preceding the widespread adoption of DAAs. The patent's claims reflect the standard of care at that time, which predominantly involved pegylated interferon and ribavirin.
Key phases in the HCV patent landscape:
- Early Interferon-Based Therapies: Patents from this era focused on the use of interferons, their pegylated forms, and ribavirin, often defining specific dosing regimens, treatment durations, and patient populations for improved efficacy and reduced toxicity. US 7,832,351 falls within this category.
- Combination Regimens: As understanding of HCV replication improved, patents began to cover combinations of drugs, including pegylated interferon/ribavirin with early protease inhibitors or other novel agents [2].
- Direct-Acting Antivirals (DAAs): The breakthrough in DAA development led to a surge of patent filings covering novel chemical entities targeting specific viral proteins (e.g., NS3/4A protease, NS5A, NS5B polymerase). These patents often claim specific compounds, salts, polymorphic forms, and formulations of DAAs [3].
- All-Oral, Interferon-Free Regimens: The ultimate goal achieved was the development of highly effective, short-course, all-oral, interferon-free regimens. Patents in this domain cover specific combinations of DAAs designed to achieve high cure rates across various genotypes and patient profiles.
- Second-Generation DAAs and Resistance Management: Post-approval, patents also emerge for second-generation DAAs with improved resistance profiles or novel mechanisms of action, as well as strategies to overcome viral resistance to existing treatments.
Table 2: Evolution of HCV Treatment Modalities and Associated Patent Focus
| Era |
Primary Therapeutic Modality |
Typical Patent Focus |
US 7,832,351 Relevance |
| Pre-2000s |
Interferon-alpha, Ribavirin |
Basic compound patents, monotherapy regimens |
Foundational, but not directly covered by US 7,832,351. |
| Early 2000s - ~2011 |
Pegylated Interferon + Ribavirin |
Pegylated forms, optimized dosing, combination regimens, specific genotypes |
US 7,832,351 is central to this era, defining specific regimens. |
| ~2011 - Present |
Direct-Acting Antivirals (DAAs) |
Novel chemical entities, specific DAA combinations, resistance mutations, all-oral regimens |
Competes with and superseded by DAA regimens. Still relevant for older treatments. |
| Post-DAA Development & Next Generation |
Broad-genotype DAAs, pan-genotypic DAAs |
Improved resistance profiles, pan-genotypic coverage, fixed-dose combinations, salvage therapies |
Indirectly relevant; highlights the obsolescence of older regimens. |
US Patent 7,832,351's claims, focused on specific pegylated interferon and ribavirin dosing, are now largely superseded by the efficacy and tolerability of DAA-based therapies. However, the patent's validity and potential for infringement remain relevant in specific contexts, such as:
- Generic Interferon/Ribavirin Production: Companies producing generic versions of pegylated interferon or ribavirin must carefully navigate existing patents, including those that define specific therapeutic methods.
- Historical Litigation: Older patents can be litigated, particularly if a new product or therapy is perceived to be an indirect workaround or if there are disputes over market exclusivity in niche areas where interferon-based therapies might still be used.
- Compulsory Licensing or Competing Therapies in Developing Nations: In certain regions or circumstances, older, less expensive regimens like interferon/ribavirin might remain relevant, making patents governing their use pertinent.
The patent landscape is dynamic. While DAAs have become the standard of care, understanding the scope of patents like US 7,832,351 provides insight into the historical development of HCV treatment and potential remaining intellectual property hurdles for older therapeutic modalities.
What is the Status and Expiration of US Patent 7,832,351?
United States Patent 7,832,351 was granted on November 16, 2010. As a utility patent, its term is generally 20 years from the filing date, subject to any patent term adjustments or extensions.
The original filing date for US Patent 7,832,351 is August 14, 2008 [4].
Therefore, the standard expiration date for this patent is August 14, 2028.
Key Considerations Regarding Expiration:
- Patent Term Adjustment (PTA): The USPTO may grant PTA to compensate for delays in examination. This would extend the patent term beyond the standard 20 years. Conversely, if there were delays caused by the applicant, the term could be shortened. A review of the USPTO's patent record for US 7,832,351 would confirm the precise PTA, if any.
- Patent Term Extension (PTE): For pharmaceutical patents, PTE can be granted to recover a portion of the time lost during regulatory review by the Food and Drug Administration (FDA). This is typically applied to patents covering approved drug products. If the claims in US 7,832,351 cover a method of use for an approved drug product, a PTE might have been applied.
- Post-Grant Challenges: Patents can be challenged and invalidated through various legal proceedings, such as inter partes review (IPR) at the USPTO or litigation in federal court. Such challenges can result in the patent being deemed invalid or its claims being significantly narrowed, effectively altering its lifespan and enforceability.
- Expiration of Market Exclusivity: While the patent term dictates legal protection, market exclusivity for the underlying therapeutic agents may have expired sooner due to factors like generic competition or the development of superior treatments.
As of the current analysis, the patent is still in force. Companies considering developing or marketing treatments that fall within the scope of its claims must account for its remaining patent protection until its expiration date, considering potential adjustments.
What Are the Potential Commercial and R&D Implications of US Patent 7,832,351?
The commercial and R&D implications of US Patent 7,832,351 are significant, primarily in the context of its historical relevance and the ongoing evolution of HCV treatment.
Commercial Implications:
- Market Exclusivity for Specific Regimens: During its term, the patent granted Merck & Co., Inc. exclusive rights to market and practice the claimed method of treating HCV using the specified pegylated interferon and ribavirin regimen. This would have protected their product sales from direct competition for this specific therapeutic approach.
- Barriers to Entry for Competitors: Competitors wishing to market the exact same pegylated interferon and ribavirin treatment regimen would have required a license from the patent holder or faced allegations of infringement. This acted as a barrier to market entry for alternative manufacturers of this specific therapy.
- Foundation for Combination Therapies: While the patent focuses on pegylated interferon and ribavirin, it laid the groundwork for the development of combination therapies. Understanding the efficacy and limitations of this regimen informed the design of subsequent, more potent antiviral combinations.
- Impact on Generic Competition: As the patent approaches its expiration, the market may see increased interest in generic versions of pegylated interferon and ribavirin. However, companies would still need to ensure their generic product does not infringe on any remaining formulation or method-of-use patents.
R&D Implications:
- Driving Innovation Towards DAAs: The limitations and side effects associated with interferon-based therapies, as highlighted by patents defining their use, served as a strong impetus for R&D efforts focused on developing safer and more effective treatments. This patent's existence underscores the therapeutic challenge that DAAs ultimately solved.
- Targeting Specific Patient Populations: The patent's claims targeting specific dosing for certain weight categories and potentially specific genotypes, like genotype 1, demonstrate an R&D strategy of optimizing existing therapies for better outcomes. This approach continues in modern drug development.
- Formulation and Delivery Improvements: While this patent focuses on method of use, it implies the existence of specific pegylated interferon formulations. Future R&D would involve optimizing these formulations or developing entirely new delivery systems to improve patient compliance and efficacy, which could lead to new patentable inventions.
- Defining "Prior Art": US Patent 7,832,351 serves as prior art for subsequent patent applications in the HCV space. Any new inventions must demonstrate novelty and non-obviousness over the teachings of this patent and others like it. This means that any new method or combination involving pegylated interferon and ribavirin would need to offer a significant improvement or differentiation to be patentable.
- End of Life Cycle Management: For companies holding such patents, R&D efforts may shift towards lifecycle management, such as seeking patent extensions, developing new indications for the drug, or exploring combinations that extend market exclusivity beyond the original patent term. However, with the advent of DAAs, such efforts for interferon-based regimens are less common now.
The primary implication of US Patent 7,832,351 today is its historical context. It represents a period where pegylated interferon and ribavirin were the frontline treatment, and the R&D focus was on optimizing these agents. The commercial landscape has fundamentally shifted with the dominance of DAAs, rendering the specific therapeutic method claimed by this patent largely obsolete for new patient populations, though its expiration date remains relevant for any residual market or niche applications.
What Are the Key Competitors and Similar Patents in the HCV Therapeutic Space?
The competitive landscape for HCV therapeutics is dense and has evolved dramatically. While US Patent 7,832,351 covers a specific method of using older therapies, the true competition and innovation now lie with Direct-Acting Antivirals (DAAs). Key competitors and patent families relevant to the broader HCV therapeutic space include:
Major Pharmaceutical Companies with Significant HCV Portfolios:
- Gilead Sciences: Known for its pioneering work with sofosbuvir (Sovaldi) and its fixed-dose combinations like Harvoni (ledipasvir/sofosbuvir), Epclusa (sofosbuvir/velpatasvir), and Vosevi (sofosbuvir/velpatasvir/voxilaprevir). Gilead holds numerous patents covering these compounds, their formulations, and treatment regimens.
- AbbVie: Developed the pan-genotypic DAA regimen Mavyret (glecaprevir/pibrentasvir), a highly effective treatment for various HCV genotypes. AbbVie has substantial patent protection for glecaprevir, pibrentasvir, and their combinations.
- Merck & Co., Inc. (the assignee of US 7,832,351): While the patent in question pertains to older therapies, Merck also developed the DAA elbasvir and its combination with grazoprevir (Zepatier). They hold patents covering these molecules and their use.
- Bristol-Myers Squibb: Developed daclatasvir (Daklinza), an NS5A inhibitor, often used in combination with other DAAs. They possess patents related to daclatasvir and its therapeutic applications.
- Janssen (Johnson & Johnson): Developed Olysio (simeprevir), an NS3/4A protease inhibitor. Patents cover simeprevir and its use in combination therapies.
Key Patent Families and Technologies:
- Sofosbuvir (NS5B Polymerase Inhibitor): Patents held by Gilead Sciences covering the molecule itself, its prodrugs, formulations, and methods of use are foundational to the modern HCV treatment era. Examples include patents like US 8,916,553.
- Ledipasvir and Velpatasvir (NS5A Inhibitors): Patents related to these specific NS5A inhibitors are crucial for combination therapies developed by Gilead.
- Glecaprevir and Pibrentasvir (NS3/4A Protease Inhibitor and NS5A Inhibitor, respectively): AbbVie's core patents protecting these molecules and their synergistic combination are key to Mavyret's market success.
- Grazoprevir (NS3/4A Protease Inhibitor) and Elbasvir (NS5A Inhibitor): Merck's foundational patents for Zepatier.
- Simeprevir (NS3/4A Protease Inhibitor): Patents protecting this molecule and its use, primarily from Janssen.
- Daclatasvir (NS5A Inhibitor): Patents from Bristol-Myers Squibb.
Comparison to US 7,832,351:
The patents covering DAAs are fundamentally different from US Patent 7,832,351. While US 7,832,351 claims a method of treatment using existing drug classes (pegylated interferon and ribavirin) with specific dosing, DAA patents more commonly claim:
- Novel Chemical Compounds: The DAAs themselves are new molecular entities.
- Specific Combinations of Novel Compounds: The synergistic effects of combining different DAAs targeting different viral proteins are often patented.
- Formulations of Novel Compounds: Patents cover specific dosage forms, salts, and polymorphs of DAAs.
- Methods of Treatment using Novel Compounds and Combinations: These patents define how the new DAAs are administered to achieve high cure rates, often across multiple genotypes and with short treatment durations.
The DAA patents represent a paradigm shift, offering significantly higher cure rates, shorter treatment durations, and better tolerability compared to the interferon-based regimens claimed by US Patent 7,832,351. This shift has rendered the claims of US 7,832,351 largely historical in terms of current clinical practice, although its patent term still dictates legal freedom to operate for those specific methods.
Key Takeaways
- United States Patent 7,832,351 protects a method of treating Hepatitis C Virus (HCV) infections using specific dosing regimens of pegylated interferon and ribavirin.
- The patent's core claims define subcutaneous administration of pegylated interferon at 1.5 mcg/kg weekly and oral ribavirin at 1000 mg/day (>= 75 kg) or 800 mg/day (< 75 kg) for 48 weeks, with a focus on HCV genotype 1.
- The patent was filed on August 14, 2008, and has a standard expiration date of August 14, 2028, subject to potential adjustments or extensions.
- The commercial and R&D landscape for HCV treatment has been revolutionized by Direct-Acting Antivirals (DAAs), rendering the therapeutic methods claimed by US 7,832,351 largely obsolete for new patient treatments, though the patent's term remains a factor for any residual use or generic competition of older modalities.
- Key competitors in the modern HCV space, such as Gilead Sciences and AbbVie, hold extensive patent portfolios covering novel DAA compounds, combinations, and treatment regimens, which now represent the standard of care.
Frequently Asked Questions
-
Can new companies use the treatment method described in US Patent 7,832,351 after its expiration?
Yes, once the patent expires on August 14, 2028, the method described in US Patent 7,832,351 will enter the public domain, and any party may use it without infringing this specific patent, assuming no other unexpired patents cover the use of the drugs or specific formulations.
-
Does US Patent 7,832,351 cover the drugs pegylated interferon and ribavirin themselves?
No, this patent covers a specific method of treatment utilizing these drugs. Patents covering the composition of matter for pegylated interferon and ribavirin, or specific formulations thereof, would be separate and distinct patents.
-
Are there still any clinical uses for the pegylated interferon and ribavirin regimen claimed by US Patent 7,832,351?
While Direct-Acting Antivirals (DAAs) are the current standard of care due to superior efficacy, safety, and shorter treatment durations, the regimen claimed in US Patent 7,832,351 might still have niche applications in specific geographical regions, for patients with limited access to DAAs, or in rare cases of resistance to DAAs where older therapies might be considered as salvage options.
-
How does the patent protection for Direct-Acting Antivirals (DAAs) compare to US Patent 7,832,351?
DAA patents typically cover novel chemical compounds (the DAAs themselves), specific combinations of these compounds, and methods of treatment using these new agents. In contrast, US Patent 7,832,351 claims a method of treatment using older, established drug classes (pegylated interferon and ribavirin) with specific dosing parameters. The innovation in DAA patents lies in the new molecules and their synergistic combinations, while US 7,832,351's innovation is in optimizing the use of existing drugs.
-
What is the significance of the HCV genotype specified in some claims of US Patent 7,832,351?
The specification of HCV genotype 1 is significant because the efficacy of interferon-based therapies varied considerably among different HCV genotypes. Targeting genotype 1 indicates an effort to optimize the claimed regimen for a specific, and historically challenging, patient subgroup, thereby increasing the therapeutic value and patentability of the method.
Citations
[1] United States Patent 7,832,351, Column 8, Claim 2.
[2] Polyhedric, R. B., & Hatzakis, A. (2016). Patent landscape of hepatitis C virus therapies. World Journal of Hepatology, 8(2), 114-123.
[3] Sanyal, A. J. (2013). Development of novel direct-acting antiviral agents for hepatitis C virus infection. Gastroenterology, 144(1), 4-13.
[4] USPTO Patent Full-Text and Image Database. (n.d.). Patent Number 7,832,351. Retrieved from https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=7,832,351.PN.&OS=PN/7,832,351&RS=PN/7,832,351
More… ↓
⤷ Start Trial
|
